🇺🇸 FDA
Pipeline program

Empagliflozin 20 mg

DEMETER

Phase 3 small_molecule active

Quick answer

Empagliflozin 20 mg for Metabolic Syndrome is a Phase 3 program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
COLLEGIUM PHARMACEUTICAL, INC
Indication
Metabolic Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials